CD38: T Cell Immuno-Metabolic Modulator

Activation and subsequent differentiation of T cells following antigenic stimulation are triggered by highly coordinated signaling events that lead to instilling cells with a discrete metabolic and transcriptional feature. Compelling studies indicate that intracellular nicotinamide adenine dinucleotide (NAD+) levels have profound influence on diverse signaling and metabolic pathways of T cells, and hence dictate their functional fate. CD38, a major mammalian NAD+ glycohydrolase (NADase), expresses on T cells following activation and appears to be an essential modulator of intracellular NAD+ levels. The enzymatic activity of CD38 in the process of generating the second messenger cADPR utilizes intracellular NAD+, and thus limits its availability to different NAD+ consuming enzymes (PARP, ART, and sirtuins) inside the cells. The present review discusses how the CD38-NAD+ axis affects T cell activation and differentiation through interfering with their signaling and metabolic processes. We also describe the pivotal role of the CD38-NAD+ axis in influencing the chromatin remodeling and rewiring T cell response. Overall, this review emphasizes the crucial contribution of the CD38−NAD+ axis in altering T cell response in various pathophysiological conditions.


1.Introduction :-
In addition to various co-stimulatory and co-inhibitory T cell receptors, ectonucleotidases that regulate the extracellular concentration of nucleotides, are also considered pivotal in modulating T cell response [11,12]. It has been shown that ectonucleotidases like CD39 and CD73 can promote an immunosuppressive microenvironment in various diseases like cancer, autoimmunity, and allergy through generation of adenosine by sequential cleavage of extracellular ATP to AMP and AMP to adenosine [11]. By doing this conversion, CD39 and CD73 impinge on purinergic signaling in T cells by limiting the availability of purinergic mediator ATP, and hence mitigate the pro-inflammatory response of T cells [12]. This demonstrates the emerging role of ectonucletidases as key regulator in determining the generation of inflammatory vs.
immunosuppressive T cell response.
In recent years, CD38, another critical ectonucleotidase has gained prominence as an important regulator of T cell activation and function [13,14]. CD38 is a multifunctional transmembrane ectoenzyme that belongs to nicotinamide adenine dinucleotide (NAD+) glycohydrolase/adenosine 5'-diphosphate-ribosyl cyclase gene family. The enzymatic activity of CD38 not only catalyzes the cyclization of NAD+ to cyclic ADP-ribose (cADPR), but also hydrolyzes cADPR to form ADP-ribose (ADPR) [15]. Interestingly, it has been shown that a small amount of NAD+ gets cyclized by CD38 to produce cADPR, while the majority is hydrolyzed to ADPR [16]. This observation led to the proposition that the major enzymatic activity of CD38 is NAD+ glycohydrolase (NADase), but not ADP-ribosyl cyclase. In addition to NAD+, CD38 has also been shown to hydrolyze nicotinamide adenine dinucleotide phosphate (NADP) into nicotinic acid adenine dinucleotide phosphate (NAADP) via a base-exchange reaction [17]. However, the reaction requires an acidic pH and high (millimolar) concentration of nicotinic acid, the conditions can only be attained in vitro but hardly possible in vivo [17]. In fact, this notion was further supported by the observation that shRNA mediated knockdown of CD38 in Jurkat T cells had no effect in altering the intracellular concentration of NAADP, suggesting the dispensable role of CD38 in generating NAADP [18].
Numerous studies suggest that cADPR generated by the enzymatic action of CD38 acts as a second messenger for intracellular Ca2+ mobilization in several cells [19,20]. This indicates a plausible involvement of CD38 in regulating T cell activation [14,21], given the unequivocal role of Ca2+ signaling in triggering T cell activation. In fact, it has been reported that the expression of CD38 accompanies T cell activation and predominantly localizes to the immune synapse in close contact with T cell receptor (TCR) [22]. Moreover, the NAD+ glycohydrolase (NADase) activity of CD38 which determines the intracellular level of NAD+ [16], a principal metabolite regulating diverse biochemical and cellular processes further evinces the pivotal role of CD38 in regulating T cell functionality. Here in, we will focus on how CD38 is involved in Activation and subsequent differentiation of T cells following antigenic stimulation are triggered by highly coordinated signaling events that lead to instilling cells with a discrete metabolic and transcriptional feature. Compelling studies indicate that intracellular nicotinamide adenine dinucleotide (NAD+) levels have profound influence on diverse signaling and metabolic pathways of T cells, and hence dictate their functional fate. CD38, a major mammalian NAD+ glycohydrolase (NADase), expresses on T cells following activation and appears to be an essential modulator of intracellular NAD+ levels. The enzymatic activity of CD38 in the process of generating the second messenger cADPR utilizes intracellular NAD+, and thus limits its availability to different NAD+ consuming enzymes (PARP, ART, and sirtuins) inside the cells. The present review discusses how the CD38-NAD+ axis affects T cell activation and dierentiation through interfering with their signaling and metabolic processes. We also describe the pivotal role of the CD38-NAD+ axis in influencing the chromatin remodeling and rewiring T cell response. Overall, this review emphasizes the crucial contribution of the CD38+NAD+ axis in altering T cell response in various pathophysiological conditions. regulating T cell-mediated immunity.

CD38− NAD+ Axis in Health and Diseases
CD38 was discovered as a cell surface marker present on the thymocytes and activated T cell surface and initially termed as T10 [23,24]. The enzymatic activities of CD38 generating ADPR and cADPR were described by Berthelier et al. and De Flora et al. [25,26]. A decade later, this molecule drew attention after Edward Chini and colleagues unearthed the role of CD38 as a major NAD+ catabolizing enzyme having a number of pathophysiological implications in aging, infection, and tumorigenesis [15].
High expression of CD38 has often been found to be associated with several hematological malignancies [27,28]. For example, the pathogenic role of CD38 have been implicated in multiple myeloma (MM), where tumor cells exhibit high surface expression of CD38 [29,30]. Likewise, CD38 expression is reported in other hematological tumors including B cell-chronic lymphocytic leukemia, acute myeloid leukemia, acute lymphocyte leukemia, and acute promyelocytic leukemia [31]. Owing to high CD38 expression, therapeutic interventions targeting CD38 are being devised for various hematological malignancies. Recently, monoclonal antibody targeting CD38 has been approved by FDA for the treatment of patients with refractory MM [27,28,32,33]. Conversely to hematological tumors, malignant cells from solid tumors do not express CD38. However, emerging studies are indicating that immune cells of both lymphoid and myeloid origin present at solid tumor sites exhibit high cell surface expression of CD38, which negatively correlates with the prognosis of the disease [13,34,35].
In contrast to causal attribution of CD38 in hematological malignancies many intriguing pieces of evidence suggest that However, CD38 has also been characterized as a marker of terminally exhausted T cells, which are refractory to the PD1 blockade mediated functional rejuvenation [50,51]. In agreement with this observation, a study from our group also reported that expression of CD38 caused metabolic aberration and compromised anti-tumor response by T cells [13].
These intriguing evidences suggest a complex role of CD38 in regulating T cell response through intervening multiple cellular and molecular pathways.

CD38 Mediated Signaling in Activated T Cells
The importance of CD38 in regulating T cell function is increasingly appreciated owing to their multifunctional enzymatic activity (both NADase and ADP-ribosyl cyclase), which can deplete intracellular NAD+ level and generates key signaling mediator, cADPR in T cells concomitantly [14]. However, in lymphocytes, CD38 is present on the plasma membrane in a type II conformation, with its catalytic domain exposed extracellularly [53,54]. In addition to mobilizing Ca2+ from ER, the role of CD38 induced cADRP-RyR axis in regulating T cell functionality has also been reported. It was shown that splenocytes from CD38 deficient mice with M. avium infection were skewed towards Th2 type and secreted lower IFNγ , which correlated with their compromised ability to limit mycobacterial burden

CD38− NAD+ Axis in Regulating T cell Fate and Function
CD38 has been identified as a critical modulator of NAD+ metabolism owing to its NADase activity [15,16]. NAD+ is a crucial cellular metabolite being, directly and indirectly, involved in a plethora of signaling pathways. Intracellular NAD+ level dependent regulation of various signaling cascades is shown to be mediated through two important enzymes, Poly Sirt (Sirt1-6) are a class of proteins that possess either mono-ADP-ribosyltransferase, or deacylase activity, including deacetylase, desuccinylase, demalonylase, demyristoylase, and depalmitoylase activity [73]. Several studies reveal that overexpression of CD38 leads to the depletion of intracellular NAD+ levels and thus has a profound influence on the activity of the NAD+ consuming enzymes (PARP and Sirt), which regulate cellular homeostasis [16].
Alongside the PARPs and Sirt, whose activity is principally governed by the availability of the intracellular NAD+, there exists another class of NAD+ consuming enzyme named as ADP-ribosyl transferases or ARTs that act as extracellular NAD+ sensors. There are two major isoforms of ARTs-ART2.1 and ART2.2, which are reported to play a critical role in T cell activation and fate determination [74-77]. In addition, directly interfering early events of TCR signaling through producing cADPR, the NADase activity of CD38 could also have a profound influence on various aspects of T cell activation and differentiation. In the next few sections, we will be elaborating, how CD38 dependent modulation of NAD+ levels affect different cellular events in T cells, which in turn dictate the functional and phenotypic outcome of T cells.

CD38 NAD Axis in T Cell Immuno-Metabolism
Given the role of CD38 in modulating intracellular NAD levels, its involvement in regulating the metabolic commitment of T cells is becoming apparent [1,2]. Several studies are shedding light on CD38 NAD -Sirt1 axis as an important metabolic checkpoint having enormous contribution in varied aspects of cellular energy metabolisms, including glycolysis, oxidative phosphorylation (OXPHOS), glutaminolysis, which are inherently associated with dictating T cell functional fate [2][3][4].
A recent study from our group illustrated that the ablation of the surface expression of the CD38 in CD4 T cells exhibited intrinsically higher levels of NAD , which contributed to the rewiring of metabolic commitment and altered mitochondrial + + 2+ + − + + − + + dynamics that renders T cells more effective in terms of anti-tumor immunity [2]. The study further reported that although targeting CD38 concomitantly enhanced Sirt1 activity, but the metabolic changes were independent of Sirt1, as Sirt1 deficiency had minimal effect on metabolic changes observed in CD38 CD4 T cells [2]. This indicated the possibility that other CD38 dependent pathways could play an essential role in this process. One possibility could be the involvement of other Sirt like Sirt3, as it is reported that CD38 promotes the age-related decline of NAD which causes mitochondrial dysfunction and reduced OXPHOS in Sirt3 dependent manner [5]. The metabolic dysfunctionality observed in the CD38 expressing tumor-infiltrating CD4 T cells [2] could also be mediated by the loss of anti-oxidant potential of T cells. Studies published by our group and others have shown that expression of CD38 inversely regulates the antioxidant potential of cells, and loss of CD38 in CD4 T cells significantly increased the expression of various anti-oxidant genes including Trx1, Trx2, Sod1, Sod2, and Nrf2 [2,6]. Recently, it has been shown that elevated ROS generation in T cells as a result of diminished anti-oxidant (glutathione) level, led to compromised activation of mTOR and reduced expression of NFAT and Myc, an important transcription factor drives glutaminolysis in T cells [7]. Therefore, further investigation in this direction is needed to delineate the Sirt1 independent role of CD38 in regulating the metabolic features of T cells.
NAD -Sirt1 axis, which is regulated by the expression of CD38 plays a vital role in determining the metabolic commitment of T cells. Importantly, Sirt1 has shown to promote oxidative phosphorylation and mitochondrial metabolism [8][9][10][11], which has appeared to be crucial in the differentiation of memory T cell [12,13]. Sirt1 mediated regulation of mitochondrial metabolism is mainly attributed to proteins belonging to peroxisome proliferators γ co-activator 1 (PGC-1) family, PGC1α and PGC1β [11,14]. The activity of PGC1α and PGC1β are known to be promoted via Sirt1 mediated deacetylation. The activation of these proteins facilitates mitochondrial biogenesis and subsequently OXPHOS [14]. Thus, it might be hypothesized that hyperactivity of CD38 alleviates Sirt1 activity and hence perturb mitochondrial biogenesis and OXPHOS, which impinge on memory T cell differentiation. It should also be noted that Sirt1 could promote the differentiation of long-lived T cells with heightened anti-tumor potential through inhibiting the activity of PPARγ [15,16], which suppresses the induction of lipolysis in T cells [16], a prerequisite for memory T cell differentiation [16,17].
Therefore, it seems that the expression of CD38 on T cells by limiting intracellular NAD levels and Sirt1 activity exerts metabolic perturbations, which ultimately affects T cell differentiation and functionality. Further investigation is thus needed to delineate the intricate mechanisms which would be useful in devising drugable target to improve the metabolic fitness and hence the functionality of T cells (Figure 2). CD38, by virtue of its NADase activity, has shown to perturb cellular homeostasis of different NAD consuming enzymes reported to act as epigenetic modifiers and hence can alter the functional fate of T cells [18]. Emerging evidence suggests that CD38-NAD axis has a profound influence in regulating the intracellular levels of various metabolites including α-ketoglutarate (α-KG), 2-hydroxyglutarate (2-HG), and signaling mediator like ROS, which are reported to play a pivotal role in orchestrating the epigenetic landscape of T cells [2,19,20]. Thus, a detailed discussion of these pathways is of utmost importance in the aspect of T cell differentiation, development, and function.

Metabolites Mediated Epigenetic Regulation
As discussed in the previous section, elevated expression of CD38 on T cells inversely regulates glutaminolysis, a predominant pathway of yielding α-KG, which act as a co-factor of histone and DNA demethylases [2,19]. Recently, it has been reported that α-KG mediated H3K27 demethylation can be linked to the increased effector cytokines (IFN-γ and IL-2) production by mouse CD8 T cell [21]. The study arouses the possible association of CD38 dependent metabolic rewiring as a critical cellular event regulating the epigenetic modification of T cells and hence their functional state. This is supported by the recent studies showing that expression of CD38 facilitates T cell exhaustion at the tumor site, which is refractory to restore their functionality by immune checkpoint blockade therapy [22]. This phenomenon is in part due to the extensive epigenetic remodeling of CD38 expressing stable exhausted T cells (CD38 PD1 CD101 T cells) [22]. Although the detailed mechanisms underpinning CD38 dependent epigenetic modification of T cells has not been fully explored, altered metabolic commitment of CD38 expressing T cells could play an essential role in this process.
Several studies have reported that a balance between intracellular level of a-KG and 2-HG, a metabolite produced by isocitrate dehydrogenase 1 and 2 (IDH1/2), are capable of altering histone methylation and chromatin accessibility in various cell types [19,23]. α-KG and 2-HG are mutually antagonistic in nature and are found to modulate epigenetic modification of T cells via affecting the activity of ten-eleven Translocases (TET), DNA, and histone methylases [19]. The intricate balance between α-KG and 2-HG in instilling epigenetic modification has recently been implicated in fate determination of Th17 and Treg [23]. This is in accordance with the early observation showing that glutaminolysis derived α-KG negatively regulates Treg differentiation [24]. The mechanism could be of further importance in explaining the elevated expression of CD38, particularly on Treg with heightened suppressive activity [25]. It is possible that CD38 mediated negative regulation of glutaminolysis, and hence the production of α-KG and subsequently 2-HG, maintains demethylation state of FoxP3 promotor that results in increased Treg stability.

Sirt1 Dependent Epigenetic Regulation
NAD -Sirt1 axis, which is inversely regulated by CD38 expression, has been reported to be an important epigenetic modifier owing to its deacetylation activity [26]. The Sirt1 induced epigenetic regulation can be achieved in three distinct mechanisms, viz., a) regulation of chromatin structure by histone deacetylation, b) regulating the activity of transcription factor by deacetylation, and c) regulation of other epigenetic enzymes by deacetylation [26].
Sirt1 can deacetylate lysine residues of different histone marks, including H3K9Ac, H4K16Ac, and H1K26Ac, as silencing Sirt1 using RNAi approach in human cells led to a global increase in H3K9Ac and H4K16Ac [27]. In human CD8 memory T cells, increased histone acetylation at H3K9 (H3K9Ac), is associated with the activate transcription of EOMES, PRF1, and GZMB loci [28]. However, whether Sirt1 has any role in regulating the acetylation of H3K9 at EOMES, PRF1, and GZMB loci of memory CD8 T cells has not been fully explored and thus warrants further investigations .
The role of Sirt1 on imparting distinctive epigenetic signature on T cells could also be mediated through regulating the activity of epigenetic enzymes. It has recently been demonstrated that CD38 ablation mediated elevation of Sirt1 in CD8 T cells from SLE patients is capable of deacetylating enhancer of zeste homolog 2 (Ezh2), an enzyme catalyzing methylation of H3K27 which ultimately causes transcriptional repression [29]. The study further reported that Sirt1 mediated deacetylation of Ezh2 rendered it inactive, resulting in increased transcription of T-bet, EOMES, and Runx3 in CD8 T cells due to reduced Ezh2 mediated H3K27me3 in these gene loci [29]. The study, thus, pointed out the role of CD38 NAD -Sirt1 axis mediated regulation of Ezh2 in determining the cytotoxic potential of CD8 T cells. Ezh2 mediated H3K27 tri-methylation is also reported to regulate Th1, Th2 and Treg differentiation. Ezh2 and increased H3K27 tri-+ + + + + + + − + methylation inhibits Th1 and Th2 differentiation as it facilitates the silencing of genes encoding lineage-specific cytokines (like Ifng and il13 for Th1 and Th2, respectively) and transcription factors (T-bet and GATA3 for Th1 and Th2, respectively) [30].
Conversely, expression of Ezh2 promotes Treg cell stability and function, as genetic ablation of Ezh2, specifically in FoxP3 expressing T cells, has shown to suppress Treg cell signature gene FoxP3 [31]. From a recent clinical study, it was found that T cells from Rheumatoid arthritis (RA) patients exhibited lower Ezh2, which regulated T cell differentiation through promoting epigenetic modification [32]. From in vitro studies, it was concluded that attenuation of Ezh2 led to the downregulation of RUNX1, and promoted SMAD7 which synergistically dampened the TGFβ signaling events, essential for generation of Tregs [32]. Therefore, it seems reasonable to argue that in addition to directly influencing FoxP3 activity and stability, Sirt1 could indirectly affect the fate of Treg via regulating the enzymatic activity of Ezh2 [33,34] (Figure 2).

Conclusion
From the above discussion, the multifaceted roles of CD38 in T cell differentiation, development, and different aspects of T cell health is quite evident. In addition to controlling the different aspects of T cell activation by interplaying with the TCR downstream signaling pathways, the competition of CD38 with several post-translational and epigenetic modifiers for occupancy of NAD+ has been shown to be one of the key dictating factors driving discrete T cell fates. Even this intricate balance appears to be decisive in regulating the suppressive potential of Treg. It can be speculated from the existing studies that Sirt1 mediated deacetylation of FoxP3, a post-translational event that diminishes the suppressive potential of Treg could be instrumental in regulating the differential suppressive activity between CD38hi and CD38lo Treg. In addition to Sirt1 axis, CD38 mediated metabolic rewiring could also play a crucial role in this context through orchestrating the cellular balance of -KG and 2-HG; key glutaminolysis derived metabolites have shown to regulate epigenetic modification. Therefore, it seems that although CD38 expression during activation of T cells might be necessary for mediating early activation events, its stabilization could have a differential effect in defining the functional outcome of different T cell subsets.
It is also evident from recent studies that CD38 has a crucial role in driving stable exhaustion of T cells, which is refractory to the PD-1 mediated functional rejuvenation. Although the precise mechanism(s) yet to decipher, it seems that